Wixela Inhub 250 ug/1

Wixela Inhub 250 ug/1 is a combination of fluticasone propionate and salmeterol, designed for respiratory use. This powder inhaler is used to manage asthma symptoms and improve breathing. It contains 60 doses per inhaler.

Wixela Inhub 250 ug/1 is primarily used for the maintenance treatment of asthma in adults and children. It helps to control and prevent asthma symptoms by reducing inflammation and opening airways. This medication is not intended for immediate relief of acute asthma attacks.

Common effects of Wixela Inhub 250 ug/1 may include throat irritation, hoarseness, and coughing. Some users might experience headaches or tremors. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Wixela Inhub 250 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. Patients should be aware of potential allergic reactions and discontinue use if severe side effects occur. Regular monitoring may be required for long-term use.

Wixela Inhub 250 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other respiratory medications should be used with caution.